Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial von Herbst, R.S., Baas, P., Perez-Gracia, J.L., Felip, E., Kim, D.-W., Han, J.-Y., Molina, J.R., Kim, J.-H., Dubos Arvis, C., Ahn, M.-J., Majem, M., Fidler, M.J., Surmont, V., de Castro, G., Garrido, M., Shentu, Y., Emancipator, K., Samkari, A., Jensen, E.H., Lubiniecki, G.M., Garon, E.B.

Volltext

Prognostic Factors for Survival After Recurrence of Stage III Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation Therapy von Sen, N, Bonomi, P, Fidler, M.J, Batus, M, Sher, D.J

Volltext

Patient and Institutional Predictors of Trimodality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC) in the National Cancer Database von Sher, D.J, Liptay, M.J, Fidler, M.J

Volltext

Association Between Trimodality Therapy and Survival in Patients With Stage III Non-Small Cell Lung Cancer (NSCLC) in the National Cancer Database von Sher, D.J, Fidler, M.J, Liptay, M.J

Volltext

Survival Outcomes in Patients With Nonsquamous Non-Small Cell Lung Cancer Treated With Pemetrexed- Versus Nonpemetrexed-Based Chemoradiation Therapy von Ziel, E, Batus, M, Fidler, M.J, Bonomi, P.D, Sher, D.J

Volltext

EP08.01-037 Association of Baseline NLR and BMI with Clinical Outcomes in NSCLC Patients Treated with Immunotherapy Alone Versus Chemo-Immunotherapy von Moudgalya, H., Basu, S., Bonomi, P., Fidler, M.J., Borgia, J.A.

Volltext

EP08.02-119 RNA Sequencing to Characterize Pathways in EGFR-mutated Non-Small Cell Lung Cancer von Yun, N., Naqib, A., Borgia, J.A., Fidler, M.J.

Volltext

P1.08D.03 Induction Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-Small Cell Lung Cancer (NSCLC) von Sanborn, R.E., Hanes, D., Shaker, D., Fidler, M.J., Gurubhagavatula, S., Chang, S.-C., Redmond, W.L.

Volltext

PO-1451 Neutrophil-lymphocyte ratio dynamics associated with survival after SBRT for stage I-II lung cancer von Shahamatdar, S., King, K., Roy, S., Batus, M., Fidler, M.J., Bonomi, P., Marwaha, G., Chowdhary, M.

Volltext

EP03.05-04 RNA Sequencing to Characterize Pathways in Patients with EGFR-mutated Non-Small Cell Lung Cancer von Yun, N.K., Pope, C., Cagin, K.M., Naqib, A., Borgia, J.A., Fidler, M.J.

Volltext

Esophageal carcinoma advances in treatment results for locally advanced disease: review von Herskovic, A., Russell, W., Liptay, M., Fidler, M.J., Al-Sarraf, M.

Volltext

Pembrolizumab (pembro) vs docetaxel (doce) for previously treated, PD-L1–expressing NSCLC: Updated outcomes of KEYNOTE-010 von Herbst, R.S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J.L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. Dubos, Ahn, M.-J.A., Majem, M., Fidler, M.J., De Castro, G., Garrido, M., Shentu, Y., Lubiniecki, G.M., Garon, E.B.

Volltext

Evaluation of Sentinel Lymph Node Drainage Patterns in Early-Stage Oral Cavity Cancer von Azem, O., King, K., Joshi, N.P., Tajudeen, B., Escobedo, P., Bhayani, M., Al-Khudari, S., Stenson, K.M., Jelinek, M., Papagiannopoulos, P., Fidler, M.J.

Volltext

Phase I/II study of a novel MDM-2 inhibitor (APG-115) in TP53 wild type salivary gland cancers von Pearson, A.T., Muzaffar, J., Bellile, E., Worden, F.P., Chung, C.H., Rosenberg, A., Vokes, E., Fidler, M.J., Brenner, J.C., Zhai, Y., Fu, T., Winkler, R., Swiecicki, P.

Volltext

P2.12-16 Significant Tumor Regression and Toxicity with Nivolumab Plus Ipilimumab in Small Cell Lung Cancer Patients Following Radiation von Gilmore, B., Batus, M., Fidler, M.J., Marwaha, G., Bonomi, P.

Volltext

OA10.02 Psychosocial Distress in Patients with Driver-Mutant Lung Cancer von Head, L., Yun, N., Basu, S., Rynar, L., Feldman, J., Batus, M., Bonomi, P., Jelinek, M., Fidler, M.J.

Volltext

MA14.04 Sexual Health Assessment in Women with Lung Cancer (SHAWL) Study von Duma, N., Acharya, R., Wei, Z., Seaborne, L., Heisler, C., Fidler, M.J., Elkins, I., Feldman, J., Moore, A., King, J., Kushner, D.

Volltext

MA06.05 Consolidation Nivolumab and Ipilimumab or Nivolumab Alone Following Concurrent Chemoradiation for Patients with Unresectable Stage III NSCLC von Durm, G.A., Mamdani, H., Althouse, S., Jabbour, S., Ganti, A., Jalal, S., Chesney, J., Naidoo, J., Hrinczenko, B., Fidler, M.J., Leal, T., Feldman, L., Fujioka, N., Hanna, N.

Volltext

Scar Bolus Omission During Adjuvant Intensity Modulated Radiation Therapy (IMRT) Does Not Increase Risk of Incisional Recurrence for Oral Cavity Cancers von Hogue, C., Fidler, M.J., Showel, J., Al-Khudari, S., Stenson, K.M., Sen, N.

Volltext

PS02.13 Rapid Progression in 100% PDL-1 expressing NSCLC von Fidler, M.J., Harting, R., Batus, M., Bonomi, P.

Volltext